Stool DNA screening for colorectal cancer: Opportunities to improve value with next generation tests

John B Kisiel, David A. Ahlquist

Research output: Contribution to journalArticle

9 Scopus citations


General adoption of the screening tests for colorectal cancer (CRC) by patients, health care professionals, medical centers, and third party payers rests on a favorable assessment of value. Reported cost-effectiveness estimates of stool DNA testing for CRC screening incorporated performance assumptions based on data from the first generation tests. Given the substantial technical advances in stool DNA testing that have occurred subsequently, estimates of value will need to be revisited. This review briefly examines the early cost-effectiveness estimates for stool DNA screening and looks ahead at how the next generation tests might improve such value estimates for CRC screening.

Original languageEnglish (US)
Pages (from-to)301-308
Number of pages8
JournalJournal of Clinical Gastroenterology
Issue number4
StatePublished - Apr 2011



  • adenoma detection
  • colorectal cancer screening
  • stool DNA testing

ASJC Scopus subject areas

  • Gastroenterology

Cite this